Erratum: Design of wide-spectrum inhibitors targeting coronavirus main proteases (PLoS Biology 3:10 DOI: 10.1371/journal.pbio.0030324);Design of wide-spectrum inhibitors targeting coronavirus main proteases

PLoS Biology

Volumn 3, Issue 10, 2005, Pages 2044-

  Yang, Haitao ^a,b   Xie, Weiqing ^c   Xue, Xiaoyu ^a,b   Yang, Kailin ^a,b   Ma, Jing ^a,b   Liang, Wenxue ^d   Zhao, Qi ^a,b   Zhou, Zhe ^a,b   Pei, Duanqing ^e   Ziebuhr, John ^f   Hilgenfeld, Rolf ^g   Kwok, Yung Yuen ^h   Wong, Luet ⁱ   Gao, Guangxia ^a,b   Chen, Saijuan ^d   Chen, Zhu ^d   Ma, Dawei ^c   Bartlam, Mark ^a,b   Rao, Zihe ^a,b  

^a TSINGHUA UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^e GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY OF LÜBECK   (Germany)

^h UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; PROTEINASE INHIBITOR 12; PROTEINASE INHIBITOR N 1; PROTEINASE INHIBITOR N 3; PROTEINASE INHIBITOR N 9; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; 3C LIKE PROTEASE, SARS CORONAVIRUS; 3C LIKE PROTEINASE, CORONAVIRUS; 3C-LIKE PROTEASE, SARS CORONAVIRUS; 3C-LIKE PROTEINASE, CORONAVIRUS; ANTIVIRUS AGENT; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; OLIGOPEPTIDE; OXAZOLE DERIVATIVE; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG DESIGN; ENTEROVIRUS; ENZYME ACTIVITY; ENZYME ASSAY; GASTROENTERITIS; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; NONHUMAN; PROTEINASE INHIBITION; SARS CORONAVIRUS; SEQUENCE HOMOLOGY; STATISTICAL SIGNIFICANCE; STRUCTURE ANALYSIS; VIRUS REPLICATION; ANIMAL; BINDING SITE; CELL CULTURE; CHEMISTRY; CORONAVIRUS; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; KINETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; PROTEIN CONFORMATION; SYNTHESIS; TRANSMISSIBLE GASTROENTERITIS VIRUS; X RAY CRYSTALLOGRAPHY;

ANIMALIA; CORONAVIRUS; TRANSMISSIBLE GASTROENTERITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CORONAVIRUS; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DRUG DESIGN; HUMANS; KINETICS; MICE; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; OXAZOLES; PROTEIN CONFORMATION; PYRROLIDINONES; SARS VIRUS; TRANSMISSIBLE GASTROENTERITIS VIRUS; TUMOR CELLS, CULTURED; VIRAL PROTEINS;

EID: 26444498493     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.0030428     Document Type: Erratum

References (52)

1. Lai MMC, Holmes KV (2001) Coronaviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology, 4th ed. Philadelphia: Lippincott Williams and Wilkins. pp. 1163-1179
2. Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, et al. (2005) Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 79: 884-895.
3. van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, et al. (2004) Identification of a new human coronavirus. Nat Med 10: 368-373.
4. Spaan WJM, Cavanagh D (2004) Coronaviridae. In: Virus taxonomy: Eighth report of the International Committee on Taxonomy of Viruses. London: Elsevier-Academic Press. pp. 945-962
5. Pereira HG (1989) Coronaviridae. In: Porterfield JS, editor. Andrewes' viruses of vertebrates, 5th ed. London: Baillière Tindall. pp. 42-57
6. Siddell SG, Ziebuhr J, Snijder EJ (2005) Coronaviruses, toroviruses, and arteriviruses. In: Mahy BWJ, ter Meulen V, editors. Topley and Wilson's microbiology and microbia infections, 10th ed. London: Hodder Arnold. pp. 823-856
7. Myint SH (1995) Human coronavirus infections. In: Siddell SG, editor. The Coronaviridae. New York: Plenum. pp. 389-401
8. Gagneur A, Sizun J, Vallet S, Legr MC, Picard B, et al. (2002) Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: A prospective study. J Hosp Infect 51: 59-64.
9. Holmes KV (2001) Coronaviruses. In: Knipe DM, Howley PM, editors. Fields virology, 4th ed. Philadelphia: Lippincott Williams and Wilkins. pp. 1187-1197
10. Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, et al. (2003) Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 331: 991-1004.
11. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967-1976.
12. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, et al. (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348: 1953-1966.
13. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, et al. (2003) Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362: 263-270.
14. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361: 1319-1325.
15. Bacha U, Barrila J, Velazquez-Campoy A, Leavitt SA, Freire E (2004) Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43: 4906-4912.
16. Blanchard JE, Elowe NH, Huitema C, Fortin PD, Cechetto JD, et al. (2004) High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem Biol 11: 1445-1453.
17. Jain RP, Pettersson HI, Zhang J, Aull KD, Fortin PD, et al. (2004) Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J Med Chem 47: 6113-6116.
18. Kao RY, Tsui WH, Lee TS, Tanner JA, Watt RM, et al. (2004) Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol 11: 1293-1299.
19. Tanner JA, Zheng BJ, Zhou J, Watt RM, Jiang JQ, et al. (2005) The adamantine-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol 12: 303-311.
20. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, et al. (2004) Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A 101: 10012-10017.
21. Steinhauer DA, Holland JJ (1986) Direct method for quantitation of extreme polymerase error frequencies at selected single base sites in viral RNA. J Virol 57: 219-228.
22. Peiris JS, Guan Y, Yuen KY (2004) Severe acute respiratory syndrome. Nat Med 10: S88-S97.
23. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, et al. (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278.
24. Chinese SARS Molecular Epidemiology Consortium (2004) Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303: 1666-1669.
25. Vijgen L, Keyaerts E, Moes E, Thoelen I, Wollants E, et al. (2005) Complete genomic sequence of human coronavirus OC43: Molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol 79: 1595-1604.
26. van der Most RG, Spaan WJ (1995) Coronavirus replication, transcription and RNA recombination. In: Siddell SG, editor. The Coronaviridae. New York: Plenum. pp. 11-31
27. Kusters JG, Jager EJ, Niesters HG, van der Zeijst BA (1990) Sequence evidence for RNA recombination in field isolates of avian coronavirus infectious bronchitis virus. Vaccine 8: 605-608.
28. Wang L, Junker D, Collisson EW (1993) Evidence of natural recombination within the S1 gene of infectious bronchitis virus. Virology 192: 710-716.
29. de Haan CA, Masters PS, Shen X, Weiss S, Rottier PJ (2002) The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 296: 177-189.
30. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, et al. (2004) CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 101: 15748-15753.
31. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, et al. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450-454.
32. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, et al. (2005) Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 102: 7988-7993.
33. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, et al. (2003) The genome sequence of the SARS-associated coronavirus. Science 300: 1399-1404.
34. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, et al. (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300: 1394-1399.
35. Ziebuhr J, Snijder EJ, Gorbalenya AE (2000) Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol 81: 853-879.
36. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R (2003) Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science 300: 1763-1767.
37. Anand K, Palm GJ, Mesters JR, Siddell SG, Ziebuhr J, et al. (2002) Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J 21: 3213-3224.
38. Yang H, Yang M, Ding Y, Liu Y, Lou Z, et al. (2003) The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A 100: 13190-13195.
39. Hegyi A, Ziebuhr J (2002) Conservation of substrate specificities among coronavirus main proteases. J Gen Virol 83: 595-599.
40. Liu S, Hanzlik RP (1992) Structure-activity relationships for inhibition of papain by peptide Michael acceptors. J Med Chem 35: 1067-1075.
41. Hanzlik RP, Thompson SA (1984) Vinylogous amino acid esters: A new class of inactivators for thiol proteases. J Med Chem 27: 711-712.
42. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, et al. (1999) Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A 96: 11000-11007.
43. Tian WX, Tsou CL (1982) Determination of the rate constant of enzyme modification by measuring the substrate reaction in the presence of the modifier. Biochemistry 21: 1028-1032.
44. Roberts A, Paddock C, Vogel L, Butler E, Zaki S, et al. (2005) Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol 79: 5833-5838.
45. Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, et al. (2003) Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 47: 3907-3916.
46. Hsyu PH, Pithavala YK, Gersten M, Penning CA, Kerr BM (2002) Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob Agents Chemother 46: 392-397.
47. Ziebuhr J, Heusipp G, Siddell SG (1997) Biosynthesis, purification, and characterization of the human coronavirus 229E 3C-like proteinase. J Virol 71: 3992-3997.
48. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. In: Carter CW Jr, Sweet RM, editors. Macromolecular crystallography, part A. New York: Academic Press. pp. 307-326
49. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.
50. Jones TA, Zou JY, Cowan SW, Kjeldgaard (1991) Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47: 110-119.
51. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Cryst 26: 283-291.
52. Meara JP, Rich DH (1995) Measurement of individual rate constants of irreversible inhibition of a Cys proteinase by an epoxysuccinyl inhibitor. Bioorg Med Chem Lett 5: 2277-2282.